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ABSTRACT 
Background: Heart block requiring a pacemaker is common after self-expandable 
transcatheter aortic valve replacement (SE-TAVR); however, conduction abnormalities may 
improve over time. Optimal device management in these patients is unknown. 
Objective: To evaluate the long-term, natural history of conduction disturbances in patients 
undergoing pacemaker implantation following SE-TAVR.  
Methods:  All patients who underwent new cardiac implantable electronic device (CIED) 
implantation at Michigan Medicine following SE-TAVR placement between 01/01/2012 and 
9/25/2017 were identified. Electrocardiogram and device interrogation data were examined 
during follow-up to identify patients with recovery of conduction.  Logistic regression 
analysis was used to compare clinical and procedural variables to predict conduction 
recovery. 
Results: Following SE-TAVR, 17.5% of patients underwent device placement for new 
atrioventricular (AV) block. Among 40 patients with an average follow up time of 17.1±8.1 
months, 20 (50%) patients had durable recovery of AV conduction. Among 20 patients 
without long term recovery, 4 (20%) had transient recovery. The time to transient conduction 
recovery was 2.2±0.2 months with repeat loss of conduction at 8.2±0.9 months. On 
multivariate analysis, larger aortic annular size (OR 0.53 [ 0.28 - 0.86]/mm, P=0.02) 
predicted lack of conduction recovery. 
Conclusions: Half of the patients undergoing CIED placement for heart block following SE-
TAVR recovered AV conduction within several months and maintained this over an extended 
follow up period. Some patients demonstrated transient recovery of conduction before 
recurrence of conduction loss. Larger aortic annulus diameter was negatively associated with 
conduction recovery.  
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INTRODUCTION 
The advent of transcatheter aortic valve replacement (TAVR) has led to a new paradigm for 
the treatment of severe aortic stenosis
1
. While overall safety outcomes are attractive, a 
common complication of TAVR is the development of high-grade or complete 
atrioventricular (AV) conduction block which can occur in 8-40% of patients
2, 3
. Many 
patients who require a permanent pacemaker post-TAVR eventually recover AV conduction 
and do not remain pacemaker dependent 
4, 5
. The significance of this recovery and the optimal 
device-management strategy in these patients are unknown. Delaying implantation 
immediately post-TAVR may identify those patients whose conduction block is a transient 
phenomenon. However, the majority of devices post-TAVR are placed within 48 hours
6, 7
. 
This is done both to facilitate patient recovery and discharge, as well as for patient safety 
given the lack of predictors on recurrence of heart block and the highly variable time to 
conduction recovery. 
Pacemaker implantation is higher with the use of self-expandable valves 
8, 9
. These prostheses 
exert a continual outward force post-deployment which could impact long-term recovery of 
conduction. In this study, we sought to evaluate the long-term, natural history of conduction 
disturbances in patients receiving cardiac implantable electronic devices (CIED) following 
TAVR using self-expandable valves and to determine long-term pacing requirements.  
METHODS 
Study Subjects 
The subjects of this study were patients who underwent pacemaker or implantable cardiac 
defibrillator placement due to conduction disturbances in the periprocedural period (within 
two weeks) after TAVR using self-expandable valves. All patients at Michigan Medicine 
who underwent TAVR between 01/01/2012 and 9/25/2017 were identified through the 
Society for Thoracic Surgeons and the American College of Cardiology Transcatheter Valve 
Therapy (STS/ACC TVT) registry. Patients who had balloon expandable valves, those with 
existing CIEDs, and those who had CIEDs placed for reasons other than new atrioventricular 
block were excluded. AV block was defined as continuous or intermittent third-degree heart 
block, second degree type II heart block, or symptomatic second degree type I AV block. 
Patients who did not have a minimum of twelve months of follow-up (due to either death, 
loss of CIED related follow-up, or less than 12 months of CIED follow-up at the time of the 
study) were excluded. The University of Michigan Institutional Review Board approved the 
study protocol prior to data collection. 
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Data Collection 
Baseline demographic, clinical, and procedural data were obtained from the STS/ACC TVT 
registry or through review of medical records where appropriate. Aortic annulus perimeter 
was derived from computed tomography (CT) planimetry performed for pre-procedural 
planning. Imaging and measurements were performed in accordance with the SCCT Expert 
Consensus document
10
. Calculated area oversizing was derived from the following formula: 
oversizing (%) = (TAVR perimeter/annulus perimeter -1) x100
11, 12
. 
At each follow-up device interrogation, native conduction was assessed by temporarily 
programming the CIED to VVI 30. Patients were routinely evaluated at one week and two 
months post implantation; follow-up then occurred every six months unless clinicians felt 
more frequent in-office evaluation was warranted. Device intracardiac electrograms and 
EKGs were reviewed when available to characterize AV node conduction into normal (1:1 
AV conduction with a PR interval <200ms), 1
st
 degree AV block, 2
nd
 degree type I AV block, 
or third-degree AV block. For patients in atrial fibrillation, complete heart block was defined 
as a regular junctional rhythm at less than 50 bpm. Patients were deemed to have no recovery 
of AV nodal conduction if they had complete heart block, high grade AV block, or a native 
ventricular rate of less than 50 bpm in the absence of normal AV nodal conduction. 
Pacemaker programming mode, percentage of atrial and ventricular pacing, and sensed/paced 
AV intervals were also collected.  
Statistical Analysis  
Patients were classified into two groups based upon whether or not they had sustained 
recovery of AV nodal conduction at the end of their follow-up period.  Those who had only 
transient recovery of AV nodal conduction were included in the no-recovery group. Patient 
and procedural characteristics were compared to identify factors associated with recovery of 
conduction. Data were compared using the Fisher’s exact t-test or chi-square for categorical 
variables and the student’s t-test or Mann-Whitney test for continuous variables where 
appropriate. Data is expressed as means±standard deviations or medians[interquartile range] 
where appropriate. Kaplan-Meyer curves were created to track recovery of AV node 
conduction over time. Univariate logistic regression analysis was performed. Variables with a 
univariate P value <0.10 were then incorporated into a multivariate analysis. All statistical 
testing was performed on R version 3.4.2 (R Foundation for Statistical Computing, Vienna, 
Austria). 
RESULTS 
General Population 
A total of 701 patients underwent TAVR over the study period including 524 (75%) with a 
self-expandable valve. Among the total population, 128 patients (18%) had pre-existing 
pacemakers (n=85) or ICD (n=43). Among the remaining 573 patients who underwent TAVR 
(n=422 self-expandable valve, n=151 balloon expandable valve) and did not have a pre-
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existing CIED, 14% (n=82) underwent device placement for new AV block (Figure 1). New 
CIED utilization rates among patients receiving self-expandable valves was 17.5% (74/422) 
and for patients receiving balloon expandable valves was 5% (8/151).  Age, pre-existing 
conduction block, the use of self-expandable valves, and diabetes were associated with an 
increased risk of requiring a CIED post TAVR implantation (Table 1). 
CIED Population 
We evaluated 40 patients who received a CIED for AV conduction abnormality following 
self-expandable TAVR. The mean patient age was 78.2±9.9 years, 53% of the population 
were male (n=21), and the mean ejection fraction was 57±14% (Table 2). Patients with less 
than one-year follow-up, patients who died within one year of follow-up, and patients with a 
CIED placed for reasons other than AV block, were excluded. Thirteen patients were 
excluded due to death which occurred during the index hospitalization for TAVR placement 
(n=3), or within 12 months due to cardiovascular (n=4) or non-cardiovascular causes (n=5).  
Cardiovascular causes of death included progression of systolic congestive heart failure in 
three patients, and diastolic heart failure in one patient. Deaths during the index 
hospitalization for TAVR included sepsis in two patients, and complications from COPD in 
one patient. There were no deaths related to CIED placement. 
Of the CIEDs implanted, 34 (85%) were dual chamber pacemakers, 4 (10%) were cardiac 
resynchronization therapy-defibrillators (CRT-D), 1 (2%) was a CRT-pacemaker, and 1 (2%) 
was a dual-chamber implantable cardioverter defibrillator (ICD). The average time between 
TAVR placement to CIED implantation was 2.4±2.4 days with 17/40 devices placed at the 
time of TAVR implantation. The indication for CIED implantation included CHB(n=33), 
mobitz type II heart block (n=2), and high grade AV block (n=5). There were no 
intraprocedural complications during CIED placement.  
Follow-up and Recovery of Conduction 
Average time of follow-up was 17.1±8.1 months, during which 50% of the patients (20/40) 
had durable recovery of AV node conduction. There was one patient with a device related 
complication over the follow-up period.  This patient had an RV lead fracture that was 
replaced without further sequela.  
The recovery of AV node conduction over the follow-up period is displayed in Figure 2. 
About half of the patients who recovered AV conduction did so within 1 month (11/20 
patients), with an average recovery time of 2.8±4.0 months. The longest time to recovery of 
conduction was 15 months.  
Patients who underwent CIED placement at the time of TAVR and those who underwent 
CIED placement later in their hospitalization had similar rates of long term conduction 
recovery (47% vs 52%, P=0.75). Time between TAVR and CIED placement had no effect on 
long-term recovery rates (P>0.05). There were no demographic differences between patients 
who underwent CIED placement at the time of TAVR (n=17) and those who underwent 
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placement later in their hospitalization (n=23) including age, sex, STS, EF, pre-existing 
conduction abnormalities, or history of atrial fibrillation/flutter (P>0.05 for all). 
Patient characteristics for those with and without recovery of AV node conduction are 
displayed in Table 2. Univariate predictors for lack of AV node recovery that were then 
included in the multivariate analysis included a history of prior cardiac surgery (OR 0.12 
[0.0.01-0.83]), LVIDd (0.37[0.13-0.91]/mm), aortic valve annular size (OR 0.50[0.29-
0.75]/mm), and atrial fibrillation or flutter (0.27[0.06-1.0])  (Table 3). On multivariate 
analysis, only aortic annular size (0.53 [ 0.28 - 0.86]/mm significantly predicted a lack of 
conduction recovery (P=0.02). 
Recovery and Later Loss of Conduction 
Among the 20 patients who remained pacemaker dependent, four patients (20%) had 
intermittent recovery of AV conduction but were pacemaker dependent by the end of the 
follow-up period (Table 4). The average time to recovery of conduction was 2.2±0.2 months 
with recurrent loss of conduction diagnosed at 8.2±0.9 months and the latest recurrent loss of 
conduction occurring at 14 months. There were no significant procedural or demographic 
differences between this group and the group which recovered conduction permanently 
(P>0.05 for all). Three patients displayed bundle branch blocks after initial recovery of 
conduction; these abnormalities were already present in two patients post-TAVR, one patient 
had progression from IVCD to a LBBB and took the longest to eventually lose conduction 
(14 months) All four patients had return to their pre-TAVR AV conduction after initial 
recovery of conduction (2/4 with return to 1
st
 degree AV block, 1/4 with persistent atrial 
fibrillation and normal ventricular rates, 1/4 with sinus rhythm and normal AV conduction 
that developed AF with normal ventricular rates).  
 
Device Settings and Follow-up EKG 
Device settings and EKG characteristics at the time of last follow up among patients who had 
recovery of conduction are shown in Table 5. Most patient’s had near normalization of their 
EKGs compared to their pre-TAVR assessment. All patients with return of conduction had 
normal AV conduction (n=7) or 1
st
 degree AV block (n=13). In 19/20 patients the mean PR 
prolongation between pre TAVR implant and follow up was 32.2±45.5ms, one patient had 2
nd
 
degree AV type I block pre-TAVR and had no AV block at follow up. Most patients (n=15) 
(75%) had abnormal QRS morphologies (LBBB n=6; RBBB n=6; IVCD n=3) at follow up, 
73% (n=11) patients had preexisting abnormal QRS morphologies and 27% (n=4) patients 
developed new abnormal QRS morphologies. The mean QRS prolongation at the time of 
follow-up was 13.8±22.8ms.  
The median ventricular pacing burden in patients who had recovered AV nodal conduction 
was 0[0-1.5]%; there was  a minority of patients (n=3) who had 1
st
 degree AV block and 
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pacing burdens>50%. This may have been minimized by programming changes to minimize 
ventricular pacing.  
 
DISCUSSION 
In this study, we reported on the natural history of conduction abnormalities in patients who 
received CIED implant for conduction abnormalities following self-expandable TAVR. We 
demonstrated that 50% of patients who received a CIED for new AV-block had recovery of 
conduction on long term follow-up. Those that underwent CIED placement at the time of 
TAVR had a similar rate of conduction recovery as those who had them placed later in the 
hospitalization stay. While the majority of patients who recovered conduction did so within 
several months, some patients will continue to display recovery up to 15 months after their 
procedure. Clinical factors associated with long-term conduction status included aortic 
annulus diameter.  
Our baseline TAVR population and incidence of CIED placement reflect real-world practices 
13
. Our mean time-to-CIED-implant (2.4 days) was similar to previously reported large cohort 
studies
6
. Similar to prior studies, older age and pre-existing conduction abnormalities were 
associated with the need for CIED placement post-TAVR 
14, 15
. In addition, in our study 
population a history of diabetes was also found to be associated with CIED placement 
following TAVR. 
Incidence and Timing of Conduction Recovery 
We reported on detailed conduction and device data over an extended follow-up period and 
found that 20/40 (50%) of patients recovered AV nodal conduction. Furthermore, these 
patients experienced only mild PR prolongation and QRS changes compared to pre-TAVR 
assessment. The majority of patients that recovered conduction did so within several months 
and maintained conduction over a follow-up period over one year.  
Acute conduction abnormalities post-TAVR are caused by mechanical compression of 
adjacent structures by the prosthesis leading to ischemic and inflammatory changes in the 
peri-nodal tissue
16
.  Sinha et al reported on an autopsy performed in a patient with new AV 
block after TAVR who died on post-operative day 10 of an unrelated cause
17
. Pathology 
showed necrosis and ischemic injury of the perinodal tissue, with sparing of the AV node and 
subendocardial septal issue. Intramyocardial hemorrhage and hematoma formation have also 
been described
18
 which can exert further local compressive forces. Resolution of these 
changes over time leads to recovery of conduction. The self-expanding valve exerts a 
persistent radial force and extends deeper in the LVOT
16, 19
. These device-specific factors 
may help explain the delayed conduction recovery seen months later though the exact 
mechanisms are unknown. A comparison between self-expanding and balloon expandable 
valves should be the focus of future studies.  
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Factors Associated with Conduction Recovery 
Several clinical factors were associated with conduction recovery. Using a multivariate 
analysis, the only significant predictor was aortic annulus size where patients with a larger 
aortic annulus were less likely to recover conduction (OR 0.53, 95% CI 0.28-0.86, p=0.02). 
The cause of this association is not clear but may be related to abnormal aortic and LVOT 
geometry resulting in increased radial forces being delivered to conductive tissue by the valve 
prosthesis. This observation is supported by procedural factors associated with new heart 
block, such as device implantation depth, angle of deployment and prosthesis to LVOT 
diameter ratios
7, 20
.  
Patients who received a CIED at the time of TAVR had similar rates of conduction recovery 
as those who had them placed later in the hospitalization. Presumably a longer duration of 
heart block prior to CIED implant would be more specific in identifying those who will have 
long-term conduction abnormalities. Waiting periods are broadly recommended though the 
optimal timing of CIED implantation is unknown
21
. Implant timing in our study was based on 
operator judgment. Prospective clinical trials are needed to better understand the effect of 
immediate versus delayed CIED implantation.  
 
Recovery and Subsequent Loss of Conduction 
In 16% of patients who recovered conduction early on, a subsequent loss of conduction was 
observed. Most patients’ ultimate loss of conduction occurred within 8 months of TAVR, 
although one patient experienced a late loss of conduction at 14 months. No clinical factors 
were associated with later loss of AV conduction, though the patient who lost conduction at 
14 months was notable for the development of a new LBBB after initial recovery of 
conduction. This ability for late recurrent loss of conduction can have important implications 
for device programming and management.  
Prior Studies 
These results contribute to a growing body of evidence that recovery of conduction is 
common in patients who undergo CIED implantation after TAVR. There is substantial 
heterogeneity in follow-up periods, methodology of conduction assessment (resting EKGs 
versus device interrogation), and definition of conduction recovery; however, reports show 
that most patients will experience partial, if not complete conduction recovery over long term 
follow up
3, 22-26
. Reported rates of long-term recovery are approximately 50-60%, consistent 
with this study. Clinical factors associated with recovery are less reliably demonstrated. A 
recent study by Kaplan et al followed 67 patients with high-grade or complete AV block 
following balloon-expandable and SEV TAVR placement and reported that only 21.9% 
remained pacemaker dependent after one year
25
. The use of SEV as well as post-balloon 
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dilation was associated with a higher rates of pacemaker dependency. In contrast, Raelson et 
al performed a similar analysis on patients undergoing both balloon-expandable and SEV and 
were unable to find predictors of recovery
23
. Our study expands on these findings by detailing 
the patterns of conduction recovery in patients who underwent device implantation following 
balloon expandable valves and highlights the risk of late loss of conduction and the 
subsequent implications for device management.  
Implications for Patient Management 
We demonstrate that TAVR induced heart block is transient in about half of the patients 
receiving a CIED following TAVR. Device programming in these patients should incorporate 
strategies to identify this recovery early and utilize device programming to limit unnecessary 
RV pacing.
27
 The use of cardiac resynchronization therapy or His bundle pacing as opposed 
to traditional right ventricular pacing is influenced in part by the anticipated pacing burden 
and cardiac function
28
. In select patients, a trial of single-chamber pacing with later upgrade 
based on long-term pacing needs may be pursued; however, device therapy must ultimately 
be tailored to an individual patient’s needs based on multiple factors.  
The observation of durable as well as transient recovery of AV conduction in these patients 
may have implications for device explantation. Elective explantation in patients who 
experience recovery of conduction is not standard of care but could reduce exposure to the 
long-term risks of implantable devices. This issue has added relevance given the expanding 
indications for TAVR and the use of these valves in lower risk and younger patients
29
. 
Patients who undergo device extraction for traditional indications (infection, device 
malfunction, vascular stenosis, et cetera) may likewise face an uncertain need for device 
reimplantation. Prior to explantation, one must keep in mind that despite apparent recovery in 
conduction, patients may still have intermittent AV conduction block requiring rare 
ventricular pacing. Device diagnostics (which are available through select CIED vendors) 
revealing if any ventricular paced beats were present over a period of time would have to be 
analyzed.  
 
LIMITATIONS 
This was a single-center, retrospective study with limited patient numbers and the results of 
this study should be confirmed with larger, multi-center studies. We focused our analysis on 
self-expandable valves and future studies should compare these findings to balloon 
expandable values. Our analysis was limited to patients who survived greater than one-year 
post-TAVR and had adequate follow up. This was done to focus the results on long term 
conduction assessment which will provide clinically meaningful implications on device 
management. We reported on all available EKG and device interrogation reports over the 
follow-up period; however, these events occurred months apart and we cannot account for 
conduction patterns between device interrogations. Patients with recovery of AV conduction 
had minimal or unchanged EKGs and minimal or no ventricular pacing burden at follow up 
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but this does not preclude transient high-grade block, rate dependent conduction 
abnormalities or sinus node dysfunction. Future studies will incorporate standardized device 
programming and follow up to better assess clinical pacing requirements.   
 
CONCLUSIONS 
 
Factors associated with an increased risk of requiring a CIED in all patients undergoing 
TAVR were age, pre-existing conduction block, the use of self-expandable valves, and 
diabetes. Despite a higher need for CIEDs in patients with heart block following self-
expandable TAVR, half of these patients will recover conduction over long term follow-up 
and this recovery can occur months after TAVR deployment. A larger aortic annulus was the 
lone clinical predictor showing less chance of conduction recovery. Highlighted in this study 
were a group of patients with transient recovery of conduction with subsequent return of heart 
block. 
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Figure 1) Study Population Selection. Included were 40 patients who underwent CIED placement for 
AV conduction abnormalities following self-expandable TAVR with a follow-up period at the time of 
this study of at least one year. TAVR - transcutaneous aortic valve replacement, ICD - implantable 
cardiac defibrillator, CIED - cardiac implantable electronic device, AV - atrioventricular.  
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Figure 2) Recovery of AV node conduction was seen in 50% of patients following self-
expandable transcutaneous aortic valve replacement. Among these patients, more than half 
recovered conduction within the first month. AV - atrioventricular; mo - months. 
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 No Post TAVR 
CIED (n=491) 
Post TAVR 
CIED (n=82) 
OR P 
Age 78.75±12.17 80.9±8.6 1.03 [ 1.01-1.05]/yr 0.02 
Male Sex (%) 57%(283) 62%(51)  0.44 
White Race (%) 93%(459) 94%(77)  0.88 
Pre-Existing 
Conduction 
Abnormality 
42%(205) 62%(51) 2.3 [ 1.4 - 3.7]  <0.001 
LVEF 57.9±15.4 56.4±14.6  0.39 
STS Risk Score 6.27±5.07 6.61±4.14  0.57 
CoreValve 71%(348) 90%(74) 3.81 [1.89 - 8.73] <0.001 
Stroke 10%(51) 11%(9)  0.83 
Smoker 46%(226) 45%(37)  0.88 
HTN 70%(398) 80%(65)  0.7 
DM 35%(176) 50%(41) 1.79 [ 1.11 - 2.87] 0.02 
Prior MI 20%(96) 20%(16)  0.79 
Prior CABG 22%(107) 22%(18)  0.97 
Prior PCI 34%(169) 31%(26)  0.68 
PAD 46%(226) 45%(37)  0.88 
AF/Flutter 34%(167) 40%(33)  0.26 
 
Table 1) Comparison of demographic and clinical data among patients with and without 
cardiac implantable electronic devices for AV block after TAVR placement. TAVR - 
transcutaneous aortic valve replacement; CIED - cardiac implantable electronic device; CI - 
confidence interval; OR - odds ratio; LVEF - left ventricular ejection fraction; STS - Society 
of Thoracic Surgeons; HTN - hypertension; DM - diabetes mellitus; MI - myocardial 
infarction; CABG - coronary artery bypass graft; PCI - percutaneous coronary intervention; 
PAD - peripheral artery disease; AF - atrial fibrillation.  
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  Recovery 
(n=20) 
No 
Recovery 
(n=20) 
P  OR [95% CI] 
     
Demographics      
Age (yrs) 80.5±10.0 75.9±9.5 0.14   
Sex(male) 40%(8) 65%(13) 0.12   
Race(white) 90%(18) 100%(20) 0.15   
STS Risk Score 5.3±2.6 6.1±3.8 0.42   
Pre-Existing Conduction 
abnormality 
70%(14) 65%(13) 0.75   
Smoker 5%(1) 10%(2) 0.56   
HTN 70%(14) 70%(14) 1   
DM 40%(8) 45%(9) 0.75   
Prior MI 15%(3) 5%(1) 0.3   
Prior PCI 20%(4) 30%(6) 0.48   
PAD 40%(8) 35%(7) 0.75   
AF/Flutter 25%(5) 55%(11) 0.05 0.27 [ 0.06 - 1.00] 
CAD (# of diseased vessels) 0.85±1.22 1.1±1.25 0.53   
Prior CABG 5%(1) 15%(3) 0.3   
Prior Cardiac Surgery (yes) 5%(1) 30%(6) 0.06 0.12 [ 0.01 - 0.83] 
       
Procedural Characteristics      
Time to implant (days) 2.4±2.1 2.4±2.8 1   
Intraprocedural placement 40%(8) 45%(9) 0.54   
Implant depth (mm) 4.1±1.2 4.1±0.9 0.74   
TAVR size (mm) 29.6±2.6 30.1±2.0 0.49   
TAVR/LVOT 1.41±0.12 1.35±0.12 0.14   
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TAVR to Aortic Annulus oversize 
(%) 
16.85±7.15 18.5±9.86 0.65   
     
Pre Lab      
Creatinine (mg/dl) 1.26±0.48 1.54±1.75 0.48   
Hemoglobin (g/dl) 12.06±1.9 12.05±2.1 0.98   
Albumin (g/dl) 3.89±0.37 3.91±0.32 0.85   
Platelet (103 /µL) 251±115 202±57 0.09   
       
Echo/Imaging      
Left Ventricular EF (%) 59.0±11.6% 55.4±16.2 0.42   
RV systolic pressure (mmHg) 45.6±13.5 50.5±9.3 0.25   
LVIDd (cm) 4.58±0.75 5.12±0.75 0.04 0.37 [ 0.13 - 0.91] 
LVIDs (cm) 3.12±0.81 3.54±1.02 0.27   
Septal Wall Thickness (cm) 1.2±0.25 1.2±0.22 0.63   
Aortic Valve Annulus (mm) 23.5±1.5 25.9±2.15 <0.01 0.50 [0.29 - 
0.75]/mm 
LVOT (mm) 21.1±2.4 22.3±2.3 0.12   
Aortic Valve Area (cm2) 0.76±0.19 0.73±0.17 0.57   
Aortic Valve Peak Velocity (m/s) 3.90±0.91 3.94±0.85 0.89   
       
Pre EKG      
PR (ms) 187.6±69.7 176.9±31.4 0.63   
QRS (ms) 121.6±23.1 116.5±28.31 0.56   
QTc (ms) 467±38.5 458.1±34 0.44   
RBBB 35%(7) 30%(6) 0.74   
LBBB 5%(1) 5%(1) 1   
IVCD 15%(3) 10%(2) 0.64   
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Fascicular Block 10%(2) 15%(3) 0.64   
 
Table 2) Comparison of demographic, clinical, and procedural data among patients with and 
without recovery of AV nodal conduction following cardiac implantable electronic device 
placement. OR - odds ratio; CI - confidence interval; STS - Society of Thoracic Surgeons; 
TAVR - transcatheter aortic valve replacement; HTN - hypertension; DM - diabetes mellitus; 
MI - myocardial infarction; PCI - percutaneous coronary intervention; PAD - peripheral 
arterial disease; AF - atrial fibrillation; CAD - coronary artery disease;  CABG - coronary 
artery bypass grafting; Cr - creatinine; Hgb - hemoglobin; LVEF - left ventricular ejection 
fraction; LVOT - left ventricular outflow tract; RV - right ventricle; LVIDd - left ventricular 
intraventricular dimension diastole; LVIDs - left ventricular intraventricular dimension 
systole; AV - atrioventricular; RBBB - right bundle branch block; LBBB - left bundle branch 
block; IVCD - intraventricular conduction delay.  
 
 
  OR [95% CI] P 
AF/flutter 0.15 [ 0.01-1.03] 0.07 
Prior Cardiac Surgery  0.13 [ 0.04-1.52] 0.14 
LVIDd 0.56 [ 0.13 - 2.15]/mm 0.39 
Aortic Annulus  0.53 [ 0.28 0.86]/mm 0.02 
 
Table 3) Multivariate analysis for predictors of conduction recovery. OR - odds ratio; CI - 
confidence interval; AF - atrial fibrillation; LVIDd - left ventricular intercavitary dimension 
diastole.  
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Patie
nt (#) 
Ag
e 
Sex STS 
Risk 
Scor
e 
EF 
(%
) 
Atrial 
rhyth
m 
PR 
duratio
n (ms) 
QRS 
widt
h 
(ms) 
QT
c 
(ms
) 
QRS 
morpholo
gy 
Time to 
Recove
ry (mo) 
Tim
e to 
Los
s 
(mo
) 
1 83.
0 
Male 3.5 60 A 
flutter 
NA 156 528 LBBB 2.0 3.9 
2 69.
8 
Male 0.9 65 AF NA 82 457 Normal 2.2 14.4 
3 91.
7 
Femal
e 
6.8 60 NSR 214 126 460 RBBB, 
LAFB 
2.3 9.7 
4 72.
0 
Femal
e 
8.1 30 NSR 224 172 452 LBBB 2.3 4.6 
 
Table 4) Characteristics of patients with transient recovery of conduction. EKG data shown 
are from the last EKG prior to the development of heart block. TAVR - transcatheter aortic 
valve replacement; STS - Society of Thoracic Surgeons; EF - ejection fraction; NSR - normal 
sinus rhythm; IVCD - intraventricular conduction delay; RBBB - right bundle branch block; 
LAFB - left anterior fascicular block; AF - atrial fibrillation; ms - milliseconds; mo - months.  
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Time to 
follow up 
EKG (days) 
Atrial 
Rhyth
m 
AV 
Conduct
ion 
Native 
Ventric
ular 
Rate 
(bpm) 
PR (ms) QRS 
(ms) 
QTc 
(ms) 
QRS 
(ms) 
Fascic
ular 
Block 
414±197 NSR: 
12, 
SB:4,     
AP: 4 
Normal: 
7 
1stºAV 
Block: 
13 
70.3±13
.5 
225±54 128±25 456±3
6 
Norm
al: 5 
LBB
B:6 
RBB
B:6 
IVCD
: 3  
LAFB: 
4 
Time to 
follow up 
Device 
Interrogation(
days) 
Device 
Mode 
%A 
pace 
%V 
pace 
Pace 
AV 
Sense 
AV 
LR    
521±226 AAI(R)
-
>DDD:
13 
DDD(
R):7 
DDI(R)
:1 
25.6±28
.5 
0[0-1.5] 220.0±6
1.4 
205.2±6
1.4 
59.3±
2.4 
   
 
Table 5) EKG and device characteristics at final follow up in patients with recovery of 
conduction. Values are mean±standard deviation or median[1
st
 quartile – 3rd quartile]. AV - 
atrioventricular; bpm - beats per minute; NSR - normal sinus rhythm; SB – sinus bradycardia; 
AP – atrial pacing; LBBB - left bundle branch block; RBBB - right bundle branch block; 
IVCD - intraventricular conduction delay; LAFB - left anterior fascicular block; LR - lower 
rate 
 
